CN1042936C - 取代的氨基喹诺酮化合物,其用途和含有它的药物组合物 - Google Patents

取代的氨基喹诺酮化合物,其用途和含有它的药物组合物 Download PDF

Info

Publication number
CN1042936C
CN1042936C CN93108210A CN93108210A CN1042936C CN 1042936 C CN1042936 C CN 1042936C CN 93108210 A CN93108210 A CN 93108210A CN 93108210 A CN93108210 A CN 93108210A CN 1042936 C CN1042936 C CN 1042936C
Authority
CN
China
Prior art keywords
group
ethyl
formula
fluoro
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93108210A
Other languages
English (en)
Chinese (zh)
Other versions
CN1086515A (zh
Inventor
木村富美夫
胜部哲嗣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries Ltd filed Critical Ube Industries Ltd
Publication of CN1086515A publication Critical patent/CN1086515A/zh
Application granted granted Critical
Publication of CN1042936C publication Critical patent/CN1042936C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN93108210A 1992-05-27 1993-05-27 取代的氨基喹诺酮化合物,其用途和含有它的药物组合物 Expired - Fee Related CN1042936C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15891292 1992-05-27
JP158912/92 1992-05-27

Publications (2)

Publication Number Publication Date
CN1086515A CN1086515A (zh) 1994-05-11
CN1042936C true CN1042936C (zh) 1999-04-14

Family

ID=15682065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93108210A Expired - Fee Related CN1042936C (zh) 1992-05-27 1993-05-27 取代的氨基喹诺酮化合物,其用途和含有它的药物组合物

Country Status (18)

Country Link
US (2) US5519016A (2)
EP (1) EP0572259A1 (2)
KR (1) KR100266305B1 (2)
CN (1) CN1042936C (2)
AU (1) AU656859B2 (2)
CA (1) CA2096998A1 (2)
CZ (1) CZ99693A3 (2)
FI (1) FI932412L (2)
HU (1) HUT64051A (2)
ID (1) ID20476A (2)
IL (1) IL105806A (2)
MX (1) MX9303158A (2)
NO (1) NO304832B1 (2)
NZ (1) NZ247720A (2)
PH (1) PH31078A (2)
RU (1) RU2124510C1 (2)
TW (1) TW234121B (2)
ZA (1) ZA933732B (2)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329600A1 (de) * 1993-09-02 1995-03-09 Bayer Ag Pyrido [1,2,3-d,e] [1,3,4] benzoxadiazinderivate
MX9700497A (es) * 1994-07-18 1997-04-30 Ube Industries Derivado de acido trifluorometilquinolinocarboxilico.
DE4425649A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Neue 1-[4-(Aminomethyl)phenyl] substituierte Chinoloncarbonsäuren
DE4425647A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Heterocyclyl-1-phenyl substituierte Chinoloncarbonsäuren
DE4425660A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 7-substituierte 1-[4-(1H-1,2,4-triazol-1-yl-methyl)phenyl] substituierte Chinoloncarbonsäuren
ES2193205T3 (es) * 1994-11-24 2003-11-01 Basilea Pharmaceutica Ag Nuevas bencil pirimidinas.
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
ES2169811T3 (es) * 1995-09-22 2002-07-16 Wakunaga Pharma Co Ltd Nuevos derivados del acido piridonacarboxilico o sus sales y agente antibacteriano que comprende el mismo como ingrediente activo.
US6001863A (en) * 1996-11-26 1999-12-14 Warner-Lambert Company Isothiazolones
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
DE69840599D1 (de) 1997-09-15 2009-04-09 Procter & Gamble Antimikrobielle chinolone, ihre zusammensetzungen und ihre verwendungen
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
IL124195A (en) * 1998-04-23 2000-08-31 Chemagis Ltd Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid
EP1362843B1 (en) * 1998-08-12 2006-06-14 Ihara Chemical Industry Co., Ltd. N-cyclopropyl-2-difluoromethoxy-3-bromoaniline and intermediate used for production thereof
ES2216606T3 (es) * 1998-12-21 2004-10-16 Aventis Pharma S.A. Derivados de la benzo-1,8-naftiridina.
CN1312131C (zh) * 2000-02-09 2007-04-25 第一制药株式会社 包含作为活性成分的吡啶酮羧酸的抗耐酸细菌药
MY127336A (en) * 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
CA2427872A1 (en) 2000-12-14 2002-06-20 The Procter & Gamble Company Antimicrobial 2-pyridones, their compositions and uses
DE60113450T2 (de) 2000-12-14 2006-07-13 The Procter & Gamble Company, Cincinnati Antimikrobielle chinolone
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
EP1476135A1 (en) * 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
WO2003099815A1 (en) 2002-05-28 2003-12-04 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
EP2161258A3 (en) 2002-11-20 2010-04-07 Japan Tabacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AU2003304460A1 (en) 2003-09-04 2005-03-29 Wockhardt Limited Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
ES2232309B1 (es) * 2003-11-13 2006-08-01 Quimica Sintetica, S.A. Procedimiento simplificado para la obtencion de gatifloxacino.
DE602005023717D1 (de) * 2004-03-10 2010-11-04 Usa Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids-related complex (arc)
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
KR100589429B1 (ko) 2004-08-31 2006-06-14 한국화학연구원 Ｎ-1 위치에 아미노피리딜기가 치환된 퀴놀론 유도체의 제조방법
US7732612B2 (en) * 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US20090156577A1 (en) * 2004-09-09 2009-06-18 Benjamin Davis 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
RU2349586C2 (ru) * 2004-09-17 2009-03-20 Сайлин Фармасьютикалз, Инк. Аналоги хинолона
CN101120004A (zh) * 2004-11-11 2008-02-06 艾其林医药公司 用作抗感染剂的8a,9-二氢-4a-h-异噻唑[5,4-b]喹啉-3,4-二酮及相关化合物
US7659399B2 (en) * 2005-01-05 2010-02-09 Achillion Pharmaceuticals, Inc. 1-thia-2,4a-diaza-cyclopenta[b]napththalene-3,4-diones and related compounds as anti-infective agents
WO2006084053A1 (en) * 2005-02-02 2006-08-10 Achillion Pharmaceuticals, Inc. 8-n-substituted-2h-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents
ATE491713T1 (de) * 2005-02-16 2011-01-15 Achillion Pharmaceuticals Inc Neue isothiazolochinolone und verwandte verbindungen als infektionsschutzmittel
JP5143000B2 (ja) 2005-07-27 2013-02-13 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗感染症薬としての８−メトキシ−９Ｈ−イソチアゾロ［５，４−ｂ］キノリン−３，４−ジオンおよび関連化合物
RS54047B1 (sr) * 2006-03-06 2015-10-30 Japan Tobacco Inc. Postupak za dobijanje jedinjenja 4-oksohinolina
US7456279B2 (en) 2006-03-28 2008-11-25 The Procter & Gamble Company Coupling process for preparing quinolone intermediates
SMP200800058B (it) 2006-03-28 2009-09-07 Procter & Gamble Sali e polimorfi malati di un acido (3s, 5s) -7- [3-ammino-5-metilpiperidinil]-1-ciclopropil-1,4-diidro-8-metossi-4-osso-3-chinolincarbossilico
CN101045724B (zh) * 2006-03-28 2011-08-17 宝洁公司 用于制备喹诺酮中间体的偶联方法
MX2008012327A (es) * 2006-03-28 2008-10-09 Procter & Gamble Un proceso de reduccion con hidruro para preparar intermedios de quinolona.
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
US7902227B2 (en) * 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
WO2009035634A2 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
CN102344457B (zh) * 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
US20090093513A1 (en) * 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
WO2009064836A2 (en) * 2007-11-15 2009-05-22 University Of Maryland, Baltimore Kynurenine-aminotransferase inhibitors
WO2009089263A2 (en) * 2008-01-07 2009-07-16 Ardea Biosciences Inc. Novel compositions and methods of use
EA201101451A1 (ru) * 2009-04-03 2012-03-30 Ачиллион Фармасьютикалз, Инк. Гидрокситиенохинолоны и родственные соединения как противоинфекционные средства
EA201101564A1 (ru) 2009-05-15 2012-07-30 Редкс Фарма Лимитед Редокс производные лекарственных средств
CN116444491A (zh) * 2023-03-30 2023-07-18 浙江工业大学 一种喹诺酮类衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0422485A2 (de) * 1989-10-12 1991-04-17 Bayer Ag Chinoloncarbonsäurederivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als antivirale Mittel
EP0470252A1 (en) * 1989-04-28 1992-02-12 Daiichi Pharmaceutical Co., Ltd. Anti-hiv drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097032A (en) * 1984-07-20 1992-03-17 Warner-Lambert Company Antibacterial agents - II
US5210193A (en) * 1986-01-17 1993-05-11 American Cyanamid Company Piperazine derivatives
US4840956A (en) * 1986-02-18 1989-06-20 Warner-Lambert Company Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
DE3705621C2 (de) * 1986-02-25 1997-01-09 Otsuka Pharma Co Ltd Heterocyclisch substituierte Chinoloncarbonsäurederivate
IT1197841B (it) * 1986-10-14 1988-12-06 Mediolanum Farmaceutici Srl Derivati pirido-benzotiazinici ad attivita' antibatterica ed a lunga durata di azione
JPH0751579B2 (ja) * 1987-11-07 1995-06-05 日本新薬株式会社 キノリンカルボン酸誘導体
JPH0754830Y2 (ja) * 1990-01-24 1995-12-18 株式会社ユニシアジェックス 荷重センサ取付構造
KR920004385A (ko) * 1990-08-09 1992-03-27 와꾸나가 기스께 신규 삼환화합물 또는 그의 염, 이의 제조방법 및 이를 함유하는 항균제
US5696132A (en) * 1991-05-28 1997-12-09 Daiichi Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470252A1 (en) * 1989-04-28 1992-02-12 Daiichi Pharmaceutical Co., Ltd. Anti-hiv drug
EP0422485A2 (de) * 1989-10-12 1991-04-17 Bayer Ag Chinoloncarbonsäurederivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als antivirale Mittel

Also Published As

Publication number Publication date
CN1086515A (zh) 1994-05-11
MX9303158A (es) 1994-04-29
HUT64051A (en) 1993-11-29
US5688791A (en) 1997-11-18
ZA933732B (en) 1993-12-15
IL105806A (en) 1998-02-22
US5519016A (en) 1996-05-21
KR100266305B1 (ko) 2000-09-15
CA2096998A1 (en) 1993-11-28
CZ99693A3 (en) 1993-12-15
AU656859B2 (en) 1995-02-16
IL105806A0 (en) 1993-09-22
NO931867L (no) 1993-11-29
NO931867D0 (no) 1993-05-24
EP0572259A1 (en) 1993-12-01
RU2124510C1 (ru) 1999-01-10
PH31078A (en) 1998-02-05
FI932412A0 (fi) 1993-05-26
AU3981593A (en) 1993-12-02
NO304832B1 (no) 1999-02-22
KR930023360A (ko) 1993-12-18
ID20476A (id) 1998-12-24
TW234121B (2) 1994-11-11
HU9301536D0 (en) 1993-09-28
NZ247720A (en) 1994-09-27
FI932412A7 (fi) 1993-11-28
FI932412L (fi) 1993-11-28

Similar Documents

Publication Publication Date Title
CN1042936C (zh) 取代的氨基喹诺酮化合物,其用途和含有它的药物组合物
CN1053189C (zh) 哒嗪并喹啉化合物
CN1094937C (zh) 具抑制法呢基转化酶作用的喹唑啉酮类
CN1118464C (zh) 新颖嘧啶衍生物及其制法
CN1161336C (zh) 作为抗病毒剂的喹啉羧酰胺
CN1090188C (zh) 新的苯并萘啶类化合物
CN1023700C (zh) 芳族及杂环甲酰胺衍生物抗肿瘤剂的制备
CN1127498C (zh) 吡啶衍生物、制备吡啶衍生物的方法及其中间体
CN1014789B (zh) 取代的桥式二氮二环烷基喹诺酮羧酸的制备方法
CN87103138A (zh) 新的喹啉衍生物及其制备方法
CN1207729A (zh) 喹啉－4－酰胺衍生物,它们的制备以及它们作为神经激肽3(nk－3)和神经激肽2(nk－2)受体拮抗剂的应用
CN1098098A (zh) 哌嗪衍生物
CN1524080A (zh) 作为pde4抑制剂的2,3-二氮杂萘酮哌啶子基衍生物
CN1328560A (zh) [1,2,4]三唑并[1,5－c]嘧啶衍生物
CN1446218A (zh) 苯并咪唑衍生物,它们的制备方法以及它们的治疗应用
CN1293674A (zh) 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
CN1096784A (zh) 含取代4(5)-氨基-1,8-二氨杂萘的治疗剂
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1042632C (zh) 吡啶酮羧酸衍生物、制备它们的中间体及药物组合物
CN1088928A (zh) 新的4，5-二氢-4-氧代-吡咯并[1，2-α]喹喔啉酮
CN100338074C (zh) 杂环化合物和以其为有效成分的脑机能改善剂
CN1756753A (zh) 苯并呋喃衍生物
CN1179962C (zh) 氮杂吲哚嗪酮衍生物和以其为有效成分的脑功能改善剂
CN1505624A (zh) 哌嗪子基衍生物及其作为pde4抑制剂的用途
CN1308325C (zh) 新的芳基－{4－卤素－4－[(杂芳基甲氨基)甲基]－哌啶－1－基}甲酮衍生物、制备方法及其作为药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee